Cosmetic agents include liquid oils in a total amount of 80 to 99.5% by weight. The liquid oils include (a) at least one liquid oil with a spreadability value (25° C.) in a range of 100 mm.sup.2/10 min to less than 800 mm.sup.2/10 min, (b) at least one liquid oil with a spreadability value (25° C.) in a range of 800 mm.sup.2/10 min to less than 1050 mm.sup.2/10 min, (c) at least one liquid oil with a spreadability value (25° C.) in a range of 1050 mm.sup.2/10 min to 1800 mm.sup.2/10 min. The weight ratio of the total amount of the oils named under (a) to the sum of the respective total quantities of the oils named under (b) and (c) is in the range of 1 to 3 to 1 to 1. The cosmetic agents are suitable as skin care oils and provide a smooth skin feel and protect the skin against drying out.

The present invention provides a method and composition for treating a neurodegenerative disease. In particular, the present invention provides a method and composition to increase DJ-1 gene expression or DJ-1 protein activity to treat a neurodegenerative disease.

This invention relates to systems and methods for evaluating the differentiality of a set of discrete random variables between two or more conditions, such as a malignant condition responding to treatment regime and one that is not. It also provides for the identification and selection of drugs that act in coordinated manner to phenocopy a genetic network of a malignant condition that responds to at least an immune checkpoint blockade agent.

This invention relates to systems and methods for evaluating the differentiality of a set of discrete random variables between two or more conditions, such as a malignant condition responding to treatment regime and one that is not. It also provides for the identification and selection of drugs that act in coordinated manner to phenocopy a genetic network of a malignant condition that responds to at least an immune checkpoint blockade agent.

Provided herein are methods for ameliorating the pathophysiology cysteine protease exotoxin comprising the step of administering to said individual an effective dose of an S-nitrosylating agent and an inositol phosphate or analog thereof.

Provided herein are methods for ameliorating the pathophysiology cysteine protease exotoxin comprising the step of administering to said individual an effective dose of an S-nitrosylating agent and an inositol phosphate or analog thereof.

Provided herein are methods for ameliorating the pathophysiology cysteine protease exotoxin comprising the step of administering to said individual an effective dose of an S-nitrosylating agent and an inositol phosphate or analog thereof.

When water pressure transfer of decorative layer or layers is carried out on an article using a water pressure transfer sheet 202 having a non-extensible decorative layer 22 providing hologram function and an extensible decorative layer 24 of print pattern sequentially from a top of said water pressure transfer sheet, a plurality of preformed cracks 26 are formed in said non-extensible decorative layer 22 of said water pressure transfer sheet 201 before said water pressure transfer sheet 202 lands on water, then an activating agent for wetting and activating said extensible decorative layer 24 is applied, and thereafter said water pressure transfer sheet lands on the water whereby water pressure transfer is carried out having high profile followability.

An object of the present invention is to provide a method for controlling skin permeability of an anionic compound and having superior safety.

An ionic liquid formed by an anionic compound and an amino acid ester is used.

The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds.